CytomX Therapeutics Stock Predictions
Trading levels for CTMX
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 1.37 | 6.76 % | |
| R2 | 1.34 | 4.60 % | ||
| R1 | 1.32 | 3.26 % | ||
| Current price: | 1.28 | |||
| Support | S1 | 1.27 | -1.06 % | |
| S2 | 1.25 | -2.39 % | ||
| S3 | 1.22 | -4.55 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 1.49 | 16.41 % | |
| R2 | 1.41 | 10.16 % | ||
| R1 | 1.38 | 7.81 % | ||
| Current price | 1.28 | |||
| Support | S1 | 0 | . | |
| S2 | 0 | . | ||
| S3 | 0 | . |
CTMX Predictions History
8 months ago
goynesq.236280 predicted that
CTMX
for Jan. 13th is going
2 years ago
Andrew Cheung predicted that
CTMX
for 2021-03-22 is going
3 years ago
Telemachos Chatzitheodorou predicted that
CTMX
for 2020-05-01 is going
$30.00 (190.70%)
4 years ago
NameNotImportant predicted that
CTMX
for 2019-05-06 is going
$10.06 (-3.18%)
4 years ago
BB.DEES..100571 predicted that
CTMX
for 2019-02-27 is going
$20.00 (52.32%)
About CytomX Therapeutics
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme... CTMX Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
